<div id="Tab1" class="Table">
<div class="Caption" lang="en"><div class="CaptionContent">
<span class="CaptionNumber">Table 1</span> <p class="SimplePara">Baseline
 demographics and disease severity characteristics for patients 
randomized to CZP at week 0, in patients with and without concomitant 
DMARD use at baseline</p> </div></div>
<div class="u-scroll-horizontal"><table>
<colgroup>
<col class="tcol1 align-left">
<col class="tcol2 align-left">
<col class="tcol3 align-left">
</colgroup>
<thead>
<tr>
<th> </th>
<th colspan="2"> <p class="SimplePara">Week 0 CZP dose combined (<em class="EmphasisTypeItalic ">N</em> = 273)</p> </th>
</tr>
<tr>
<th> </th>
<th> <p class="SimplePara">DMARD+ (<em class="EmphasisTypeItalic ">n</em> = 199)</p> </th>
<th> <p class="SimplePara">DMARD− (<em class="EmphasisTypeItalic ">n</em> = 74)</p> </th>
</tr>
</thead>
<tbody>
<tr><td colspan="3"> <p class="SimplePara">Demographic characteristics, mean (SD), unless otherwise stated</p> </td></tr>
<tr>
<td> <p class="SimplePara"> Age [years]</p> </td>
<td> <p class="SimplePara">48.4 (11.2)</p> </td>
<td> <p class="SimplePara">45.9 (12.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Female, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">106 (53.3)</p> </td>
<td> <p class="SimplePara">41 (55.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Caucasian, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">195 (98.0)</p> </td>
<td> <p class="SimplePara">73 (98.6)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Weight [kg]</p> </td>
<td> <p class="SimplePara">85.6 (18.0)</p> </td>
<td> <p class="SimplePara">84.5 (18.7)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> BMI [kg/m<sup>2</sup>]</p> </td>
<td> <p class="SimplePara">30.1 (6.3)</p> </td>
<td> <p class="SimplePara">29.9 (6.6)</p> </td>
</tr>
<tr><td colspan="3"> <p class="SimplePara">Disease characteristics, <em class="EmphasisTypeItalic ">n</em> (%), unless otherwise stated</p> </td></tr>
<tr><td colspan="3"> <p class="SimplePara">Prior use of synthetic DMARDs</p> </td></tr>
<tr>
<td> <p class="SimplePara"> 0</p> </td>
<td> <p class="SimplePara">0</p> </td>
<td> <p class="SimplePara">5 (6.8)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> 1</p> </td>
<td> <p class="SimplePara">118 (59.3)</p> </td>
<td> <p class="SimplePara">47 (63.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> ≥ 2</p> </td>
<td> <p class="SimplePara">81 (40.7)</p> </td>
<td> <p class="SimplePara">22 (29.7)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Prior anti-TNF exposure</p> </td>
<td> <p class="SimplePara">31 (15.6)</p> </td>
<td> <p class="SimplePara">23 (31.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Concomitant use of corticosteroids</p> </td>
<td> <p class="SimplePara">48 (24.1)</p> </td>
<td> <p class="SimplePara">20 (27.0)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Tender joint count (0–68 joints), mean (SD)</p> </td>
<td> <p class="SimplePara">20.2 (14.9)</p> </td>
<td> <p class="SimplePara">21.5 (15.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Swollen joint count (0–66 joints), mean (SD)</p> </td>
<td> <p class="SimplePara">10.4 (8.1)</p> </td>
<td> <p class="SimplePara">11.6 (8.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">DAS28 (CRP), mean (SD)</p> </td>
<td> <p class="SimplePara">5.0 (1.0)</p> </td>
<td> <p class="SimplePara">5.1 (1.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">HAQ-DI, mean (SD)</p> </td>
<td> <p class="SimplePara">1.28 (0.62)</p> </td>
<td> <p class="SimplePara">1.40 (0.65)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Patients with psoriasis (BSA ≥ 3%)</p> </td>
<td> <p class="SimplePara">113 (56.8)</p> </td>
<td> <p class="SimplePara">53 (71.6)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> PASI, mean (SD)</p> </td>
<td> <p class="SimplePara">11.4 (12.2)</p> </td>
<td> <p class="SimplePara">13.3 (12.8)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Patients with enthesitis (LEI &gt;0)</p> </td>
<td> <p class="SimplePara">125 (62.8)</p> </td>
<td> <p class="SimplePara">47 (63.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> LEI, mean (SD)</p> </td>
<td> <p class="SimplePara">3.1 (1.6)</p> </td>
<td> <p class="SimplePara">2.7 (1.6)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Patients with dactylitis<sup>a</sup></p> </td>
<td> <p class="SimplePara">52 (26.1)</p> </td>
<td> <p class="SimplePara">21 (28.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> LDI, mean (SD)<sup>a</sup></p> </td>
<td> <p class="SimplePara">49.1 (64.1)</p> </td>
<td> <p class="SimplePara">56.9 (49.6)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Patients with nail psoriasis (mNAPSI &gt;0)</p> </td>
<td> <p class="SimplePara">145 (72.9)</p> </td>
<td> <p class="SimplePara">52 (70.3)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> mNAPSI, mean (SD)</p> </td>
<td> <p class="SimplePara">3.3 (2.0)</p> </td>
<td> <p class="SimplePara">3.4 (2.1)</p> </td>
</tr>
</tbody>
</table></div>
<div class="TableFooter"> <p class="SimplePara">Randomized set</p> <p class="SimplePara"><em class="EmphasisTypeItalic ">Anti-TNF</em> anti-tumor necrosis factor, <em class="EmphasisTypeItalic ">BMI</em> body mass index, <em class="EmphasisTypeItalic ">BSA</em> body surface area, <em class="EmphasisTypeItalic ">CRP</em> C-reactive protein, <em class="EmphasisTypeItalic ">CZP</em> certolizumab pegol, <em class="EmphasisTypeItalic ">DAS28</em> 28-joint count Disease Activity Score, <em class="EmphasisTypeItalic ">DMARD</em> disease-modifying anti-rheumatic drug, <em class="EmphasisTypeItalic ">HAQ-DI</em> Health Assessment Questionnaire-Disability Index, <em class="EmphasisTypeItalic ">LDI</em> Leeds Dactylitis Index, <em class="EmphasisTypeItalic ">LEI</em> Leeds Enthesitis Index, <em class="EmphasisTypeItalic ">mNAPSI</em> modified nail psoriasis severity index, <em class="EmphasisTypeItalic ">PASI</em> psoriasis area severity index</p> <p class="SimplePara"><sup>a</sup>Of patients with ≥ 1 digit affected, with a difference in circumference ≥ 10%</p> </div>
</div>